Global life sciences company Abcam is one of the UK’s biggest biotech success stories. It was founded in 1998 by Cambridge postdoctoral researcher Jonathan Milner and Cambridge telecoms entrepreneur David Cleevely to sell good-quality antibody reagents. The company is now a Nasdaq-listed multi-billion-dollar business supporting over 750,000 global life-science researchers in every sector, from discovery through to clinical applications, to achieve their mission faster. Over half of all life science research papers published in 2020 cited an Abcam product. Its 12 operating sites globally employ 1,800 people, including 790 at the Cambridge HQ on the Cambridge Biomedical Campus, and support a UK and global supply chain of suppliers and distributors to deliver value within a sustainable global marketplace.
Added 21 December 2022